← Leaderboards
Richard Labaudiniere
Protego Biopharma, Inc.
$629,227
Attributed
$629,227
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $419.2K · FY2019–20$500K$375K$250K$125K$0
'19
'20
Funding mix
By agency
NIH$629,227 · 1
By mechanism
R43$629,227 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Degenerative Disorder”
- Birgit Schilling · Medical College Of Wisconsin$7,009,581
- Chang Hun Lee · Columbia University Health Sciences$5,341,536
- Frederic Geissmann · Sloan-Kettering Inst Can Research$4,469,958
- Maddalena Adorno · Dorian Therapeutics, Inc.$4,178,124
- Hang Lin · University Of Pittsburgh At Pittsburgh$3,889,833
- Seth Lawler Shipman · J. David Gladstone Institutes$3,628,777
Research focus
Degenerative DisorderAbsorptionAmyloidAffectAgingAmyloidosisAntisense OligonucleotidesBaseBindingAmyloid FibrilsBlood - Brain Barrier AnatomyAmyloidogenesisBody SystemBrainCardiacCardiomyopathiesCarpal Tunnel SyndromeCarrier Mediated TransportCerebrospinal FluidCerebrovascularBiological MarkersClinical TrialsCountryDementia
Grant awards (2)
Development of An Oral, Brain/Eye penetrating, Second Generation TTR Stabilizer for The Treatment of Transthyretin Amyloidoses$210,042
R43 · FY2020 · NS · contact PI
Development of An Oral, Brain/Eye penetrating, Second Generation TTR Stabilizer for The Treatment of Transthyretin Amyloidoses$419,185
R43 · FY2019 · NS · contact PI